Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

Sang S., Datoo MS., Otieno E., Muiruri C., Bellamy D., Gathuri E., Ngoto O., Musembi J., Provstgaard-Morys S., Stockdale L., Aboagye J., Woods D., Lawrie A., Roberts R., Keter K., Kimani D., Ndungu F., Kapulu M., Njau I., Orindi B., Ewer KJ., Hill AVS., Bejon P., Hamaluba M.

DOI

10.12688/wellcomeopenres.19795.1

Type

Preprint

Publication Date

28/05/2024

Permalink Original publication